Skip to content

A randomized controlled clinical trial of single door and double door expansive laminoplasty for cervical spondylotic myelopathy

A randomized controlled clinical trial of single door and double door expansive laminoplasty for cervical spondylotic myelopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017049
Enrollment
Unknown
Registered
2018-07-10
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical spondylotic myelopathy

Interventions

2:double door expansive laminoplasty surgery
1:single door expansive laminoplasty surgery

Sponsors

The Seventh Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients meeting the above one or more, after strict conservative treatment for half a year, have no obvious relieve symptoms: 1) More segmental cervical spondylosis (=three segments); 2) Continuous or segmental posterior longitudinal ligament ossification with obvious spinal cord compression; 3) Developmental cervical spinal stenosis.

Exclusion criteria

Exclusion criteria: 1) Ossification of the yellow ligament; 2) Patients with old cervical spine injury; 3) Patients who have undergone cervical vertebra internal fixation or decompression surgery because of cervical trauma or other reasons; 4) Patient with primary myelopathy; 5) Epidural adhesion caused by inflammatory disorders such as ankylosing spondylitis, rheumatoid arthritis, etc.; 6) Severe cervical instability; 7) Stiff cervical kyphosis with Cobb Angle > 10; 8) Paget's disease, osteomalacia or other bone metabolic diseases; 9) Systemic or local active infection; 10) Taking drugs (such as hormones) that may affect the healing of bone or soft tissue; 11) Infectious diseases, including AIDS, viral hepatitis, etc.; 12) Malignant tumor: the patient has a definite history of malignant tumor (except for non-malignant melanoma), unless the patient has received effective treatment and no clinical symptoms or signs have been found for at least 5 years; 13) Failure to accept or tolerate surgery for other reasons; 14) Refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Quality of life assessment;Neurological function assessment;Medical imaging assessment;

Countries

China

Contacts

Public ContactShaoyu Liu

The Seventh Affiliated Hospital, Sun Yat-sen university

gzsyliu@tom.com+86 13802772301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026